Klaria Year-End Report Q4 2020
Summary of the year-end reportInitiated bioequivalence registration study with Sumatriptan Alginate Film FOURTH QUARTER 2020 (OCTOBER–DECEMBER) · Net sales amounted to 0.0 MSEK (0.1 MSEK) · R&D costs for the period amounted to 17.6 MSEK (9.7 MSEK) · Profit after tax amounted to -17.0 MSEK (-5.3 MSEK) · Earnings per share for the quarter amounted to -0.34 SEK (-0.17 SEK) · Cash flow from operating activities amounted to -10.1 MSEK (-5.7 MSEK) · Cash and cash equivalents on the balance day amounted to 31.3 MSEK (2.9 MSEK) · Shareholder’s equity per December 31,